Mawer Investment Management Ltd. trimmed its position in Abbott Laboratories (NYSE:ABT – Free Report) by 5.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,118,031 shares of the healthcare product maker’s stock after selling 68,646 shares during the quarter. Mawer Investment Management Ltd. owned about 0.06% of Abbott Laboratories worth $110,495,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the company. Manning & Napier Advisors LLC bought a new stake in Abbott Laboratories in the 2nd quarter worth approximately $31,000. Foresight Capital Management Advisors Inc. bought a new position in shares of Abbott Laboratories during the 3rd quarter valued at approximately $31,000. Balance Wealth Partners LLC purchased a new position in shares of Abbott Laboratories in the third quarter valued at $34,000. Summit Securities Group LLC grew its holdings in shares of Abbott Laboratories by 41.3% in the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock valued at $37,000 after purchasing an additional 118 shares in the last quarter. Finally, Addison Advisors LLC bought a new stake in Abbott Laboratories in the second quarter worth $40,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other news, EVP Mary Moreland sold 3,500 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the sale, the executive vice president directly owned 100,791 shares of the company’s stock, valued at approximately $11,691,756. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.46% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on ABT shares. Royal Bank Of Canada decreased their price target on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, October 22nd. Citigroup dropped their price objective on shares of Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Rothschild & Co Redburn upgraded shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $119.00 to $127.00 in a report on Friday, October 2nd. TD Cowen reduced their target price on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating on the stock in a report on Thursday, October 22nd. Finally, Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $118.32.
View Our Latest Research Report on ABT
Abbott Laboratories Trading Up 1.3%
Shares of NYSE ABT traded up $1.34 during midday trading on Friday, hitting $108.59. The company’s stock had a trading volume of 6,199,121 shares, compared to its average volume of 9,559,261. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The company has a current ratio of 1.45, a quick ratio of 1.00 and a debt-to-equity ratio of 0.57. The firm has a market cap of $188.08 billion, a P/E ratio of 40.52, a price-to-earnings-growth ratio of 1.88 and a beta of 0.54. The business’s 50 day moving average is $103.93 and its two-hundred day moving average is $101.74.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. Abbott Laboratories’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.30 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.
Abbott Laboratories Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.
Abbott Laboratories Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Further Reading
- Five stocks we like better than Abbott Laboratories
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
